American Association for Cancer Research
Browse
mct-22-0721_supplementary_figure_1_suppsf1.docx (425.27 kB)

Supplementary Figure 1 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy

Download (425.27 kB)
journal contribution
posted on 2023-07-05, 08:21 authored by Bartlomiej Borek, Julita Nowicka, Anna Gzik, Marek Dziegielewski, Karol Jedrzejczak, Joanna Brzezinska, Marcin Grzybowski, Paulina Stanczak, Paulina Pomper, Agnieszka Zagozdzon, Tomasz Rejczak, Krzysztof Matyszewski, Adam Golebiowski, Jacek Olczak, Kamil Lisiecki, Magdalena Tyszkiewicz, Magdalena Kania, Sylwia Piasecka, Anna Cabaj, Paulina Dera, Krzysztof Mulewski, Jacek Chrzanowski, Damian Kusmirek, Elzbieta Sobolewska, Marta Magdycz, Lukasz Mucha, Marek Masnyk, Jakub Golab, Marcin Nowotny, Elzbieta Nowak, Agnieszka Napiorkowska-Gromadzka, Stanislaw Pikul, Radoslaw Jazwiec, Karolina Dzwonek, Pawel Dobrzanski, Michael Meyring, Krzysztof Skowronek, Piotr Iwanowski, Zbigniew Zaslona, Roman Blaszczyk

The immunosuppressive character of ARG1 and ARG2 in the tumor microenvironment (TME)

Funding

European Regional Development Fund (ERDF)

Narodowe Centrum Badań i Rozwoju (NCBR)

History

ARTICLE ABSTRACT

Pharmacologic inhibition of the controlling immunity pathway enzymes arginases 1 and 2 (ARG1 and ARG2) is a promising strategy for cancer immunotherapy. Here, we report the discovery and development of OATD-02, an orally bioavailable, potent arginases inhibitor. The unique pharmacologic properties of OATD-02 are evidenced by targeting intracellular ARG1 and ARG2, as well as long drug-target residence time, moderate to high volume of distribution, and low clearance, which may jointly provide a weapon against arginase-related tumor immunosuppression and ARG2-dependent tumor cell growth. OATD-02 monotherapy had an antitumor effect in multiple tumor models and enhanced an efficacy of the other immunomodulators. Completed nonclinical studies and human pharmacokinetic predictions indicate a feasible therapeutic window and allow for proposing a dose range for the first-in-human clinical study in patients with cancer. We have developed an orally available, small-molecule intracellular arginase 1 and 2 inhibitor as a potential enhancer in cancer immunotherapy. Because of its favorable pharmacologic properties shown in nonclinical studies, OATD-02 abolishes tumor immunosuppression induced by both arginases, making it a promising drug candidate entering clinical trials.

Usage metrics

    Molecular Cancer Therapeutics

    Categories

    Keywords

    cancer

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC